Inflammation-associated diseases encompass a range of infectious diseases and non-
infectious inflammatory diseases, which continuously pose one of the most serious threats to …

Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic
acid drug (NAD) delivery. Although their clinical applications have achieved success, the …

Upon entering the biological milieu, nanomedicines swiftly interact with the surrounding
tissue fluid, subsequently being enveloped by a dynamic interplay of biomacromolecules …

Nanomaterials are becoming important tools for vaccine development owing to their tunable
and adaptable nature. Unique properties of nanomaterials afford opportunities to modulate …

The success of mRNA vaccines during the COVID-19 pandemic has greatly accelerated the
development of mRNA therapy. mRNA is a negatively charged nucleic acid that serves as a …

Messenger RNA (mRNA)‐based therapy has emerged as a powerful, safe, and rapidly
scalable therapeutic approach that involves technologies for both mRNA itself and the …

With the great success of coronavirus disease (COVID-19) messenger ribonucleic acid
(mRNA) vaccines, mRNA therapeutics have gained significant momentum for the prevention …

Recent advancements in RNA therapeutics highlight the critical need for precision gene
delivery systems that target specific organs and cells. Lipid nanoparticles (LNPs) have …

Malignant tumors remain a primary cause of human mortality. Among the various treatment
modalities for neoplasms, tumor vaccines have consistently shown efficacy and promising …

While most nanomedicines primarily aim to stimulate the immune system against infections
or tumors, there is a growing demand for inducing immune tolerance under certain …